A retinoic acid receptor agonist tamibarotene suppresses iron accumulation in the liver.
A retinoic acid receptor agonist tamibarotene suppresses iron accumulation in the liver.
复制标题
视黄酸受体激动剂他米巴罗汀可抑制肝脏中铁的积累。
DOI：
10.1002/oby.20013
复制
发表时间：
2013
期刊：
影响因子：
6.9
通讯作者：
Osamu Yoshikawa
中科院分区：
文献类型：
--
作者：
Teruko Hino-Arinaga;Tatsuya Ide;Ryoko Kuromatsu;Ichiro Miyajima I;Kei Ogata;Reiichiro Kuwahara;Akiko Hisamochi;Takuji Torimura;Michio Sata;Osamu Yoshikawa
目的近年来，肝脏铁超载(HIO)和铁诱导的氧化应激已成为胰岛素抵抗发生发展的重要因素。本研究旨在评价维甲酸受体α/β激动剂他米巴罗汀对肝脏铁代谢的影响。我们先前的研究发现，维甲酸通过调节铁蛋白和铁蛋白的表达，增加肝脏铁的外流，从而抑制肝脏铁的聚集。设计与方法我们定量测定了饮食给药后KK-Aymice的非血红素铁含量和铁代谢相关基因的表达，以及KK-Aymice的血脂和血糖水平。结果表明，他巴罗汀显著降低血糖和肝铁，但不显著降低血清脂质，而显著降低血红蛋白的表达，而增加铁蛋白的表达。结论这些结果表明他巴罗汀是治疗HIO相关的胰岛素抵抗的一种有前景的替代药物。
ObjectiveHepatic iron overload (HIO) and iron‐induced oxidative stress have recently emerged as an important factor for the development and progression of insulin resistance. The aim of this study was to evaluate the effect of tamibarotene, a selective retinoic acid receptor α/β agonist, on hepatic iron metabolism, based on our previous findings that retinoids suppress hepatic iron accumulation by increasing hepatic iron efflux through the regulation of hemojuvelin and ferroportin expression.Design and MethodsWe quantitated the non‐heme iron content and iron metabolism‐related gene expression in the liver, and serum lipid and blood glucose levels in KK‐Aymice after dietary administration of tamibarotene.ResultsIt was demonstrated that tamibarotene significantly reduced blood glucose and hepatic iron, but not serum lipids, and that hemojuvelin expression significantly decreased while ferroportin increased, as observed previously.ConclusionsThese results suggest that tamibarotene is a promising alternative for the treatment of insulin resistance associated with HIO.